Latest filing published 11 Feb 2014 for Revance Therapeutics, Inc..
Insider track record
No signal scores available.
Jonathan Tunnicliffe: trading record in brief
All filings by Jonathan Tunnicliffe on record concern Revance Therapeutics, Inc. In total, 3 filings cover trades dated 11 February 2014.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Most recently, on 11 February 2014, the filings show a transaction in Revance Therapeutics, Inc. Most trades are made public on the day they happen. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Jonathan Tunnicliffe
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,039,382 sharesCommon StockSEC:0001209191-14-009003:0
- 658,551 sharesCommon StockSEC:0001209191-14-009003:1
- 398,717 sharesCommon StockSEC:0001209191-14-009003:2
3 of 3 declarations
